ArQule

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

ArQule (ARQL) delivered earnings and revenue surprises of 11.11% and -80.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ArQule (ARQL) Reports Q2 Loss, Misses Revenue Estimates

On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for

ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes ArQule (ARQL) a New Buy Stock

Adverum Biotechnologies

Axsome Therapeutics

Provention Bio Inc

Zynerba Pharmaceuticals

These biotech stocks have at least quadrupled in just over six months this year.

5 Best Biotech Stocks of 2019 So Far

The pharmaceutical pipeline shined, and the business doubled its cash position.

Here's Why ArQule Jumped 53.1% in June

Shares have risen by 50% since my last update piece.

ArQule Wins At EHA, More Upside Ahead In Second Half Of 2019

ArQule reported positive results from Part A of its phase 1/2 study using miransertib to treat patients with PIK3CA-related overgrowth spectrum and Proteus Syndrome.

ArQule Has A Solid Pipeline And The Ability To Gain Speedy Approval Makes It A Must Watch

Diebold Nixdorf Inc

Enphase Energy

Roku

ZIOPHARM Oncology

Pfizer

Small-cap stocks have under-performed their large cap peers in 2019, but these 7 small-cap stocks have each more than tripled this year.

The 7 Top Small-Cap Stocks Of 2019

Periodically revisiting one's thesis is a fruitful activity that will improve your asset allocation skills. In my view, talent is the prodigy child of hardworking and rigorous learning.

ArQule: Profiting From Tyrosine Kinase Inhibition

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?

ArQule (ARQL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

ArQule (ARQL) Catches Eye: Stock Jumps 8.1%

Investors are increasingly optimistic about the company.

Here's the Surprising Reason ArQule Shares Rose as Much as 11% Today

Shares of the small-cap biotech stock ArQule, Inc. (NASDAQ: ARQL) were seeing strength on brisk volume Monday.

ArQule Hits 12-Year High Following Favorable Midstage Study Results

A new day, a new batch of promising interim data from an early-stage clinical study.

Here's Why ArQule Is Soaring Again Today

ArQule (ARQL) stock is skyrocketing more than 30% as the company's blood cancer drug ARQ 531 has begun showing promise in its early going.
The post ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results appeared first on InvestorPlace.

ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results

The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.

Here's Why ArQule Shares Rose as Much as 44.7% Today

Shares of ArQule, Inc. are galloping toward a multiyear high in the wake of the presentation of a clinical trial readout.

Why Small-Cap Biotech ArQule Is Rallying

ArQule Inc. shares jumped early on Friday after the firm announced preliminary results from an early-stage study in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association (EHA) annual meeting in the Netherlands.

Why ArQule’s Early-Stage Hematology Study Could Be Transformational

Stocks were poised to ease lower on Friday morning.

ArQule Soars on Cancer Study

Shares of biotech ArQule Inc. shot up 49% toward a 12-year high in premarket trade Friday after the company announced preliminary data from a Phase 1 trial of its investigational cancer drug ARQ 531.

ArQule stock rockets 49% toward 12-year high after biotech announces Phase 1 trial results

Shares have risen by 568% since my initial article and by 81% since my January update piece.

ArQule: Updates To Thesis, EHA Presentation Looms

ArQule, Inc. (ARQL) CEO Paolo Pucci on Q1 2019 Results - Earnings Call Transcript

The oncology-focused pharma announced first-quarter 2019 operating results.

Here's Why ArQule Rose as Much as 12.7% Today

ArQule (ARQL) delivered earnings and revenue surprises of -12.50% and -20.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for ArQule Stock (ARQL)